{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:34:45Z","timestamp":1791822885866,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jhep.2025.03.019","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:12:18Z","timestamp":1743214338000},"page":"692-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":false,"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-1823","authenticated-orcid":false,"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-6761","authenticated-orcid":false,"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-0305","authenticated-orcid":false,"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen Lam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-6001","authenticated-orcid":false,"given":"Sang Cheul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-2612","authenticated-orcid":false,"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Gwang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.","family":"Norquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.03.019_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.019_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.03.019_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.03.019_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.03.019_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/1471-2407-12-390","article-title":"Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract","volume":"12","author":"Zabernigg","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2025.03.019_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40487-021-00159-z","article-title":"Understanding patient experience in biliary tract cancer: a qualitative patient interview study","volume":"9","author":"Patel","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.jhep.2025.03.019_bib7","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.3390\/cancers13205074","article-title":"Quality of life and symptom management in advanced biliary tract cancers","volume":"13","author":"Hunter","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2025.03.019_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/bjc.2016.284","article-title":"Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder","volume":"115","author":"Kaupp-Roberts","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.03.019_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.03.019_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.03.019_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2025.03.019_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1359-6349(12)70023-X","article-title":"Health-related quality of life in EORTC clinical trials \u2014 30 years of progress from methodological developments to making a real impact on oncology practice","volume":"10","author":"Velikova","year":"2012","journal-title":"Eur J Cancer Supplements"},{"key":"10.1016\/j.jhep.2025.03.019_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6606086","article-title":"Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21","volume":"104","author":"Friend","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.03.019_bib14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2025.03.019_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2025.03.019_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.03.019_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D-5L: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2025.03.019_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.03.019_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jnci\/djad240","article-title":"Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355","volume":"116","author":"Cescon","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2025.03.019_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.03.019_bib21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/cncr.33457","article-title":"Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies","volume":"127","author":"Voon","year":"2021","journal-title":"Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:56:01Z","timestamp":1757627761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0168827825002077"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}